Fumihiro Fujiki

2.3k total citations
42 papers, 580 citations indexed

About

Fumihiro Fujiki is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Fumihiro Fujiki has authored 42 papers receiving a total of 580 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 25 papers in Oncology and 23 papers in Immunology. Recurrent topics in Fumihiro Fujiki's work include Renal and related cancers (24 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (20 papers). Fumihiro Fujiki is often cited by papers focused on Renal and related cancers (24 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (20 papers). Fumihiro Fujiki collaborates with scholars based in Japan, Australia and United States. Fumihiro Fujiki's co-authors include Haruo Sugiyama, Hiroko Nakajima, Akihiro Tsuboi, Yoshitaka Oka, Yusuke Oji, Sumiyuki Nishida, Naoki Hosen, Soyoko Morimoto, Ichiro Kawase and Jun Nakata and has published in prestigious journals such as Blood, PLoS ONE and Neurology.

In The Last Decade

Fumihiro Fujiki

41 papers receiving 574 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fumihiro Fujiki Japan 15 320 292 281 48 45 42 580
Melanie Märklin Germany 13 229 0.7× 364 1.2× 295 1.0× 100 2.1× 34 0.8× 49 686
Jonas S. Heitmann Germany 14 201 0.6× 314 1.1× 303 1.1× 98 2.0× 35 0.8× 71 638
Seiji Nagano Japan 12 277 0.9× 232 0.8× 335 1.2× 58 1.2× 55 1.2× 25 607
Ilia N. Buhtoiarov United States 15 164 0.5× 614 2.1× 409 1.5× 31 0.6× 36 0.8× 30 812
Martín Bonamino Brazil 12 139 0.4× 171 0.6× 233 0.8× 100 2.1× 21 0.5× 27 460
Yu-Hsiang Chang Taiwan 8 127 0.4× 461 1.6× 402 1.4× 92 1.9× 36 0.8× 14 708
Suzanne Svobodová Australia 11 271 0.8× 389 1.3× 205 0.7× 39 0.8× 35 0.8× 14 599
Toshiaki Shirakata Japan 16 568 1.8× 271 0.9× 288 1.0× 129 2.7× 105 2.3× 27 808
Shashi Singh Pawar United States 10 309 1.0× 241 0.8× 112 0.4× 30 0.6× 70 1.6× 19 650
Junichiro Yuda Japan 10 198 0.6× 289 1.0× 268 1.0× 180 3.8× 27 0.6× 43 566

Countries citing papers authored by Fumihiro Fujiki

Since Specialization
Citations

This map shows the geographic impact of Fumihiro Fujiki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumihiro Fujiki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumihiro Fujiki more than expected).

Fields of papers citing papers by Fumihiro Fujiki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumihiro Fujiki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumihiro Fujiki. The network helps show where Fumihiro Fujiki may publish in the future.

Co-authorship network of co-authors of Fumihiro Fujiki

This figure shows the co-authorship network connecting the top 25 collaborators of Fumihiro Fujiki. A scholar is included among the top collaborators of Fumihiro Fujiki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumihiro Fujiki. Fumihiro Fujiki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Hashii, Yoshiko, Hiroko Nakajima, Fumihiro Fujiki, et al.. (2023). Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. BMC Cancer. 23(1). 167–167. 5 indexed citations
4.
Fujiki, Fumihiro, Soyoko Morimoto, Kento Inoue, et al.. (2023). Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs. Cancer Immunology Immunotherapy. 72(7). 2347–2356. 1 indexed citations
5.
Nakagawa, Natsuki, Yoshiko Hashii, Hisako Kayama, et al.. (2022). An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia. Cancer Immunology Immunotherapy. 72(1). 39–53. 14 indexed citations
6.
Fujiki, Fumihiro, Soyoko Morimoto, Ayako Isotani, et al.. (2022). T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy. Frontiers in Immunology. 13. 935465–935465. 8 indexed citations
7.
Nakajima, Hiroko, Jun Nakata, Keiko Udaka, et al.. (2021). Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunology Immunotherapy. 70(11). 3323–3335. 6 indexed citations
8.
Nakata, Jun, Kayako Isohashi, Yoshitaka Oka, et al.. (2021). Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics. 11(6). 1041–1041. 7 indexed citations
9.
Fujiki, Fumihiro, Akihiro Tsuboi, Soyoko Morimoto, et al.. (2020). Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunology Immunotherapy. 70(1). 253–263. 7 indexed citations
10.
Tsuboi, Akihiro, Naoya Hashimoto, Fumihiro Fujiki, et al.. (2018). A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology Immunotherapy. 68(2). 331–340. 43 indexed citations
11.
Nakata, Jun, Hiroko Nakajima, Soyoko Morimoto, et al.. (2018). Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides. Oncotarget. 9(89). 36029–36038. 14 indexed citations
12.
Campillo-Davó, Diana, Fumihiro Fujiki, Hans De Reu, et al.. (2018). Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing. Frontiers in Immunology. 9. 2503–2503. 28 indexed citations
13.
Kondo, Kenta, Fumihiro Fujiki, Hiroko Nakajima, et al.. (2016). An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells. Journal of Immunotherapy. 39(3). 127–139. 2 indexed citations
14.
Tatsumi, Naoya, Hiroyuki Sakamoto, Mari Fukuda, et al.. (2015). Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms. PLoS ONE. 10(6). e0130578–e0130578. 9 indexed citations
15.
Nakajima, Hiroko, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2011). Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration. Vaccine. 30(4). 722–729. 16 indexed citations
16.
Oka, Yoshitaka, Akihiro Tsuboi, Fumihiro Fujiki, et al.. (2009). WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide. Anti-Cancer Agents in Medicinal Chemistry. 9(7). 787–797. 17 indexed citations
17.
Kawakami, Manabu, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2009). Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8+ T cells in patients with myeloid malignancies. Cancer Science. 101(3). 594–600. 14 indexed citations
18.
Fujiki, Fumihiro, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2008). A WT1 protein‐derived, naturally processed 16‐mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1‐specific Th1‐type CD4+ T cells. Microbiology and Immunology. 52(12). 591–600. 15 indexed citations
19.
Oka, Yoshitaka, Akihiro Tsuboi, Olga A. Elisseeva, et al.. (2007). WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers. The Scientific World JOURNAL. 7. 649–665. 28 indexed citations
20.
Nakajima, Hiroko, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2004). WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunology Immunotherapy. 53(7). 617–624. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Melanie Märklin Breakdown of academic impact, for papers by Jonas S. Heitmann Breakdown of academic impact, for papers by Seiji Nagano Breakdown of academic impact, for papers by Ilia N. Buhtoiarov Breakdown of academic impact, for papers by Martín Bonamino Breakdown of academic impact, for papers by Yu-Hsiang Chang Breakdown of academic impact, for papers by Suzanne Svobodová Breakdown of academic impact, for papers by Toshiaki Shirakata Breakdown of academic impact, for papers by Shashi Singh Pawar Breakdown of academic impact, for papers by Junichiro Yuda
Rankless by CCL
2026